These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 35166663)

  • 1. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
    Kritzer MD; Mischel NA; Young JR; Lai CS; Masand PS; Szabo ST; Mathew SJ
    Ann Clin Psychiatry; 2022 Feb; 34(1):33-43. PubMed ID: 35166663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
    De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
    Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suicidality in treatment resistant depression: perspective for ketamine use.
    Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Słupski J; Włodarczyk A; Górska N; Szarmach J; Szałach ŁP; Wiglusz MS; Krysta K; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):258-260. PubMed ID: 31488737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.
    Wang YT; Wang XL; Lei L; Guo ZY; Kan FF; Hu D; Gai C; Zhang Y
    Eur J Clin Pharmacol; 2024 Feb; 80(2):287-296. PubMed ID: 38117332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Novel Approaches to the Treatment of Suicidality and Depression in Youth.
    Emslie GJ
    J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):500-501. PubMed ID: 37422104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
    Siegel AN; Di Vincenzo JD; Brietzke E; Gill H; Rodrigues NB; Lui LMW; Teopiz KM; Ng J; Ho R; McIntyre RS; Rosenblat JD
    J Psychiatr Res; 2021 May; 137():426-436. PubMed ID: 33774537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
    Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
    J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
    Jawad MY; Di Vincenzo JD; Ceban F; Jaberi S; Lui LMW; Gillissie ES; Alnafeesi Y; Rosenblat JD; McIntyre RS
    Expert Opin Drug Saf; 2022 Jun; 21(6):841-852. PubMed ID: 35387538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide.
    Whitaker T; Farrand KF; Thase ME
    Psychopharmacol Bull; 2024 Mar; 54(1):8-17. PubMed ID: 38449472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
    d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
    Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.
    De Berardis D; Fornaro M; Valchera A; Cavuto M; Perna G; Di Nicola M; Serafini G; Carano A; Pompili M; Vellante F; Orsolini L; Fiengo A; Ventriglio A; Yong-Ku K; Martinotti G; Di Giannantonio M; Tomasetti C
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30249029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ketamine for Major Depressive Disorder.
    Costi S
    Curr Top Behav Neurosci; 2024; 66():131-147. PubMed ID: 37922100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
    Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
    Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
    McIntyre RS; Carvalho IP; Lui LMW; Majeed A; Masand PS; Gill H; Rodrigues NB; Lipsitz O; Coles AC; Lee Y; Tamura JK; Iacobucci M; Phan L; Nasri F; Singhal N; Wong ER; Subramaniapillai M; Mansur R; Ho R; Lam RW; Rosenblat JD
    J Affect Disord; 2020 Nov; 276():576-584. PubMed ID: 32871689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS; Rosenblat JD; Nemeroff CB; Sanacora G; Murrough JW; Berk M; Brietzke E; Dodd S; Gorwood P; Ho R; Iosifescu DV; Lopez Jaramillo C; Kasper S; Kratiuk K; Lee JG; Lee Y; Lui LMW; Mansur RB; Papakostas GI; Subramaniapillai M; Thase M; Vieta E; Young AH; Zarate CA; Stahl S
    Am J Psychiatry; 2021 May; 178(5):383-399. PubMed ID: 33726522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Ketamine in the Treatment of Psychiatric Disorders.
    Derakhshanian S; Zhou M; Rath A; Barlow R; Bertrand S; DeGraw C; Lee C; Hasoon J; Kaye AD
    Health Psychol Res; 2021; 9(1):25091. PubMed ID: 35106397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketamine for depression clinical issues.
    Iqbal SZ; Mathew SJ
    Adv Pharmacol; 2020; 89():131-162. PubMed ID: 32616205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
    Kim S; Rush BS; Rice TR
    Eur Child Adolesc Psychiatry; 2021 Oct; 30(10):1485-1501. PubMed ID: 32385697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.